News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vertex Pharmaceuticals Incorporated
< Previous
1
2
3
4
Next >
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
July 02, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Second Quarter 2024 Financial Results on August 1
July 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
June 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
June 14, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
June 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming June Investor Conferences
May 22, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Jennifer Schneider Elected to Vertex Board of Directors
May 15, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports First Quarter 2024 Financial Results
May 06, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
April 18, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce First Quarter 2024 Financial Results on May 6
April 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
April 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming Investor Conferences
February 20, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
February 13, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
January 30, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
January 17, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
January 16, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
January 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
December 18, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
December 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
December 13, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex Appoints Nancy Thornberry to its Board of Directors
December 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
November 23, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex Reports Third Quarter 2023 Financial Results
November 06, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.